It was developed by GlaxoSmithKline .
Aplaviroc ( INN , codenamed AK602 and GSK - 873140 ) is a CCR5 entry inhibitor that belongs to a class of 2 , 5 - diketopiperazines developed for the treatment of HIV infection .
Aplaviroc was developed by GlaxoSmithKline .
Aplaviroc ( INN , codenamed AK602 and GSK - 873140 ) is a CCR5 entry inhibitor that belongs to a class of 2 , 5 - diketopiperazines developed for the treatment of HIV infection .